We provide evidence that this targeting concept can be used to antagonize NMDA receptors specifically in GLP-1-receptor-positive neurons to reverse obesity and correct symptoms of cardiometabolic diseases in preclinical obesity models. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.